非酒精性脂肪性肝病与非酒精性脂肪性肝炎患者肝细胞癌的影像学特征:系统综述与Meta分析
系统检索2011年1月1日至2021年7月19日MEDLINE、EMBASE和Cochrane图书馆数据库,纳入5项研究(170例患者、193个肝细胞癌病灶),用随机效应模型汇总动脉期高强化、廓清和强化包膜的合并百分比。非酒精性脂肪性肝病与非酒精性脂肪性肝炎患者肝细胞癌的动脉期高强化频率与其他病因肝细胞癌相似,但廓清和强化包膜频率相对较低;MRI强化包膜合并百分比高于CT。
要点
- 非酒精性脂肪性肝病/非酒精性脂肪性肝炎相关肝细胞癌动脉期高强化合并百分比为94.0%(95%CI 89.1-96.7%)。
- 此类肝细胞癌廓清合并百分比为72.7%(95%CI 63.3-80.4%),强化包膜合并百分比为57.5%(95%CI 45.1-69.1%)。
- MRI强化包膜合并百分比67.1% vs CT 44.7%(p=0.02),MRI高于CT。
核心结论
- 非酒精性脂肪性肝病和非酒精性脂肪性肝炎患者肝细胞癌的动脉期高强化频率与其他病因肝细胞癌相似,但廓清和强化包膜频率相对较低。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、EMBASE和Cochrane图书馆数据库2011年1月1日至2021年7月19日文献,纳入5项研究(170例患者、193个肝细胞癌病灶),采用随机效应模型汇总动脉期高强化、廓清和强化包膜的合并百分比,并按基础肝病(非酒精性脂肪性肝炎 vs 非酒精性脂肪性肝病)和影像方法(CT vs MRI)进行敏感性分析和亚组分析。
诊断标准与关键数值
- 动脉期高强化合并百分比为94.0%(95%CI 89.1-96.7%)。
- 廓清合并百分比为72.7%(95%CI 63.3-80.4%)。
- 强化包膜合并百分比为57.5%(95%CI 45.1-69.1%)。
- 非酒精性脂肪性肝病与非酒精性脂肪性肝炎之间上述三个主要特征的百分比无显著差异(p≥0.21)。
- MRI与CT的动脉期高强化合并百分比分别为94.3% vs 93.4%(p=0.82),廓清分别为70.4% vs 77.2%(p=0.38),强化包膜分别为67.1% vs 44.7%(p=0.02)。
临床应用与阅片要点
- 阅片时注意非酒精性脂肪性肝病/非酒精性脂肪性肝炎相关肝细胞癌廓清(72.7%)和强化包膜(57.5%)频率相对较低。
- MRI对强化包膜的显示合并百分比(67.1%)高于CT(44.7%),阅片时结合 modalities 判断。
- 非酒精性脂肪性肝病与非酒精性脂肪性肝炎之间三个主要影像特征的频率无显著差异(p≥0.21)。
局限性
- 纳入研究仅5项(170例患者、193个肝细胞癌病灶),样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the imaging features of hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) through a systematic review and meta-analysis.
METHODS: MEDLINE, EMBASE, and the Cochrane Library database were searched for studies providing data on imaging features of HCC in NAFLD and NASH between January 1, 2011 and July 19, 2021. Random effects models were used to calculate the pooled percentages of the three major features of arterial-phase hyperenhancement (APHE), washout, and enhancing capsule. Sensitivity analysis and subgroup analysis were performed according to underlying liver disease (NASH vs. NAFLD) and imaging modality (CT vs. MRI).
RESULTS: Five studies (170 patients with 193 HCCs) were included in the analysis. The pooled percentages of APHE, washout, and enhancing capsule were 94.0% (95% confidence interval [CI] 89.1-96.7%), 72.7% (95% CI 63.3-80.4%), and 57.5% (95% CI 45.1-69.1%), respectively. The percentages of these three major features did not significantly differ between NAFLD and NASH (p ≥ 0.21). MRI showed similar pooled percentages of APHE (94.3% vs. 93.4%, p = 0.82) and washout (70.4% vs. 77.2%, p = 0.38) to CT, but a higher pooled percentage of enhancing capsule (67.1% vs. 44.7%, p = 0.02).
CONCLUSION: HCC in patients with NAFLD and NASH had a similar frequency of APHE to HCC with other etiology. However, it showed a relatively low frequency of washout and enhancing capsule.
引用
- Park EJ, Son JH, Choi SH, et al. Imaging features of hepatocellular carcinoma in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis. Abdom Radiol (NY). 2022. PMID: 35389074. doi:10.1007/s00261-022-03499-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。